FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1993-2000 December 30, 1993 Number 27 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Brownell, A. K. W. PubMed Citation

ABSTRACT

Background Dermatomyositis is a clinically distinct myopathy characterized by rash and a complement-mediated microangiopathy that results in the destruction of muscle fibers. In some patients the condition becomes resistant to therapy and causes severe physical disabilities.

Methods We conducted a double-blind, placebo-controlled study of 15 patients (age, 18 to 55 years) with biopsy-proved, treatment-resistant dermatomyositis. The patients continued to receive prednisone (mean daily dose, 25 mg) and were randomly assigned to receive one infusion of immune globulin (2 g per kilogram of body weight) or placebo per month for three months, with the option of crossing over to the alternative therapy for three more months. Clinical response was gauged by assessing muscle strength, neuromuscular symptoms, and changes in the rash. Changes in immune-mediated muscle abnormalities were determined by repeated muscle biopsies.

Results The eight patients assigned to immune globulin had a significant improvement in scores of muscle strength (P<0.018) and neuromuscular symptoms (P<0.035), whereas the seven patients assigned to placebo did not. With crossovers, a total of 12 patients received immune globulin. Of these, nine with severe disabilities had a major improvement to nearly normal function. Their mean muscle-strength scores increased from 74.5 to 84.7, and their neuromuscular symptoms improved. Two of the other three patients had mild improvement, and one had no change in his condition. Of 11 placebo-treated patients, none had major improvement, 3 had mild improvement, 3 had no change in their condition, and 5 had worsening of their condition. Repeated biopsies in five patients of muscles whose strength improved to almost normal showed an increase in muscle-fiber diameter (P<0.04), an increase in the number and a decrease in the diameter of capillaries (P<0.01), resolution of complement deposits on capillaries, and a reduction in the expression of intercellular adhesion molecule 1 and major-histocompatibility-complex class I antigens.

Conclusions High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis.

Source Information

From the Neuromuscular Diseases Section, Medical Neurology Branch, and the Biometry and Field Studies Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.

Address reprint requests to Dr. Dalakas at the Neuromuscular Diseases Section, Bldg. 10, Rm. 4N248, NINDS, NIH, Bethesda, MD 20892.

Full Text of this Article

Related Letters:

Intravenous Immune Globulin for Dermatomyositis
Brownell A. K. W., Dalakas M. C.
Extract | Full Text  
N Engl J Med 1994; 330:1392-1393, May 12, 1994. Correspondence

This article has been cited by other articles:

• Stangel, M. (2008). Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Therapeutic Advances in Neurological Disorders 1: 115-124 [Abstract]  
• Schanz, S., Ulmer, A., Fierlbeck, G. (2008). Response of Dystrophic Calcification to Intravenous Immunoglobulin. Arch Dermatol 144: 585-587 [Full Text]  
• Manlhiot, C., Tyrrell, P. N., Liang, L., Atkinson, A. R., Lau, W., Feldman, B. M. (2008). Safety of Intravenous Immunoglobulin in the Treatment of Juvenile Dermatomyositis: Adverse Reactions Are Associated With Immunoglobulin A Content. Pediatrics 121: e626-e630 [Abstract] [Full Text]  
• Helmers, S. B., Dastmalchi, M., Alexanderson, H., Nennesmo, I., Esbjornsson, M., Lindvall, B., Lundberg, I. E (2007). Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 66: 1276-1283 [Abstract] [Full Text]  
• Chung, L., Genovese, M. C., Fiorentino, D. F. (2007). A Pilot Trial of Rituximab in the Treatment of Patients With Dermatomyositis. Arch Dermatol 143: 763-767 [Abstract] [Full Text]  
• Rafailidis, P. I., Kapaskelis, A., Falagas, M. E. (2007). Periorbital and facial swelling due to dermatomyositis. CMAJ 176: 1580-1581 [Full Text]  
• Gurcan, H. M, Ahmed, A R. (2007). Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders. The Annals of Pharmacotherapy 41: 812-823 [Abstract] [Full Text]  
• Pisoni, C. N., Cuadrado, M. J., Khamashta, M. A., Hughes, G. R. V., D'Cruz, D. P. (2007). Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46: 516-518 [Abstract] [Full Text]  
• Williams, L., Chang, P. Y., Park, E., Gorson, K. C., Bayer-Zwirello, L. (2007). Successful Treatment of Dermatomyositis During Pregnancy With Intravenous Immunoglobulin Monotherapy. Obstet Gynecol 109: 561-563 [Abstract] [Full Text]  
• Cordeiro, A C, Isenberg, D A (2006). Treatment of inflammatory myopathies.. Postgrad. Med. J. 82: 417-424 [Abstract] [Full Text]  
• Rowin, J., Amato, A. A., Deisher, N., Cursio, J., Meriggioli, M. N. (2006). Mycophenolate mofetil in dermatomyositis: Is it safe?. Neurology 66: 1245-1247 [Abstract] [Full Text]  
• Edge, J. C., Outland, J. D., Dempsey, J. R., Callen, J. P. (2006). Mycophenolate Mofetil as an Effective Corticosteroid-Sparing Therapy for Recalcitrant Dermatomyositis. Arch Dermatol 142: 65-69 [Abstract] [Full Text]  
• Raju, R., Dalakas, M. C. (2005). Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128: 1887-1896 [Abstract] [Full Text]  
• Abe, J., Jibiki, T., Noma, S., Nakajima, T., Saito, H., Terai, M. (2005). Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease. J. Immunol. 174: 5837-5845 [Abstract] [Full Text]  
• Lories, R J, Casteels-Van Daele, M, Ceuppens, J L, Van Gool, S W (2004). Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis 63: 747-748 [Full Text]  
• Dalakas, M. C. (2004). Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA 291: 2367-2375 [Abstract] [Full Text]  
• Lutz, H. U., Stammler, P., Bianchi, V., Trueb, R. M., Hunziker, T., Burger, R., Jelezarova, E., Spath, P. J. (2004). Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103: 465-472 [Abstract] [Full Text]  
• Jacobs, B. C., O'Hanlon, G. M., Bullens, R. W. M., Veitch, J., Plomp, J. J., Willison, H. J. (2003). Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126: 2220-2234 [Abstract] [Full Text]  
• Song, S., Crow, A. R., Freedman, J., Lazarus, A. H. (2003). Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 101: 3708-3713 [Abstract] [Full Text]  
• Kiely, P. D. W., Heron, C. W., Bruckner, F. E. (2003). Presentation and management of idiopathic inflammatory muscle disease: four case reports and commentary from a series of 78 patients. Rheumatology (Oxford) 42: 575-582 [Full Text]  
• Dalakas, M. C. (2002). Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59: S13-21 [Abstract] [Full Text]  
• Roddy, E., Courtney, P. A., Morris, A. (2002). Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 41: 1194-1195 [Full Text]  
• van Beekvelt, M C P, Wevers, R A, van Engelen, B G M, Colier, W N J M (2002). Muscle tissue oxygenation as a functional tool in the follow up of dermatomyositis. J. Neurol. Neurosurg. Psychiatry 73: 93-94 [Full Text]  
• Sharma, K. R., Cross, J., Ayyar, D. R., Martinez-Arizala, A., Bradley, W. G. (2002). Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy. Arch Neurol 59: 751-757 [Abstract] [Full Text]  
• Wiles, C M, Brown, P, Chapel, H, Guerrini, R, Hughes, R A C, Martin, T D, McCrone, P, Newsom-Davis, J, Palace, J, Rees, J H, Rose, M R, Scolding, N, Webster, A D B (2002). Intravenous immunoglobulin in neurological disease: a specialist review. J. Neurol. Neurosurg. Psychiatry 72: 440-448 [Abstract] [Full Text]  
• Pyne, D., Ehrenstein, M., Morris, V. (2002). The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford) 41: 367-374 [Full Text]  
• Danieli, M G, Malcangi, G, Palmieri, C, Logullo, F, Salvi, A, Piani, M, Danieli, G (2002). Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61: 37-41 [Abstract] [Full Text]  
• Choy, E. H. S., Isenberg, D. A. (2002). Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 41: 7-13 [Abstract] [Full Text]  
• Dalakas, M. C., Fujii, M., Li, M., Lutfi, B., Kyhos, J., McElroy, B. (2001). High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome. NEJM 345: 1870-1876 [Abstract] [Full Text]  
• Miller, F. W., Rider, L. G., Chung, Y.-L., Cooper, R., Danko, K., Farewell, V., Lundberg, I., Morrison, C., Oakley, L., Oakley, I., Pilkington, C., Vencovsky, J., Vincent, K., Scott, D. L., Isenberg, D. A. (2001). Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40: 1262-1273 [Abstract] [Full Text]  
• Kazatchkine, M. D., Kaveri, S. V. (2001). Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin. NEJM 345: 747-755 [Full Text]  
• Genevay, S, Saudan-Kister, A, Guerne, P-A (2001). Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective. Ann Rheum Dis 60: 635-636 [Abstract] [Full Text]  
• DALAKAS, M C (2001). Progress in inflammatory myopathies: good but not good enough. J. Neurol. Neurosurg. Psychiatry 70: 569-573 [Full Text]  
• Dalakas, M. C., Koffman, B., Fujii, M., Spector, S., Sivakumar, K., Cupler, E. (2001). A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56: 323-327 [Abstract] [Full Text]  
• Samuelsson, A., Towers, T. L., Ravetch, J. V. (2001). Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor. Science 291: 484-486 [Abstract] [Full Text]  
• Hundt, M., Manger, K., Dorner, T., Grimbacher, B., Kalden, P., Rascu, A., Weber, D., Burmester, G. R., Peter, H. H., Kalden, J. R., Schmidt, R. E. (2000). Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 39: 1301-1302 [Full Text]  
• Elkayam, O., Paran, D., Milo, R., Davidovitz, Y., Almoznino-Sarafian, D., Zeltser, D., Yaron, M., Caspi, D. (2000). Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 59: 77-77 [Abstract] [Full Text]  
• Lundberg, I., Chung, Y.-L. (2000). Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology (Oxford) 39: 7-17 [Full Text]  
• Levy, L. M., Dalakas, M. C., Floeter, M. K. (1999). The Stiff-Person Syndrome: An Autoimmune Disorder Affecting Neurotransmission of {gamma}-Aminobutyric Acid. ANN INTERN MED 131: 522-530 [Abstract] [Full Text]  
• Sorensen, P. S. (1999). Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes. Arch Neurol 56: 1025-1027 [Full Text]  
• Karussis, D., Abramsky, O. (1999). Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No. Arch Neurol 56: 1028-1032 [Full Text]  
• Dalakas, M. C. (1998). Molecular Immunology and Genetics of Inflammatory Muscle Diseases. Arch Neurol 55: 1509-1512 [Abstract] [Full Text]  
• Xu, C., Poirier, B., Duong Van Huyen, J.-P., Lucchiari, N., Michel, O., Chevalier, J., Kaveri, S. (1998). Modulation of Endothelial Cell Function by Normal Polyspecific Human Intravenous Immunoglobulins : A Possible Mechanism of Action in Vascular Diseases. Am. J. Pathol. 153: 1257-1266 [Abstract] [Full Text]  
• Mastaglia, F L, Phillips, B A, Zilko, P J (1998). Immunoglobulin therapy in inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 65: 107-110 [Abstract] [Full Text]  
• Jolles, S., Hughes, J., Whittaker, S. (1998). Dermatological Uses of High-Dose Intravenous Immunoglobulin. Arch Dermatol 134: 80-86 [Abstract] [Full Text]  
• Sewell, W A C, Brennan, V M, Donaghy, M, Chapel, H M (1997). The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. J. Neurol. Neurosurg. Psychiatry 63: 106-109 [Abstract] [Full Text]  
• Lipshultz, S. E., Orav, E. J., Sanders, S. P., Colan, S. D. (1995). Immunoglobulins and Left Ventricular Structure and Function in Pediatric HIV Infection. Circulation 92: 2220-2225 [Abstract] [Full Text]  
• Takada, H., Kishimoto, C., Hiraoka, Y. (1995). Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects. Circulation 92: 1604-1611 [Abstract] [Full Text]  
• Brownell, A. K. W., Dalakas, M. C. (1994). Intravenous Immune Globulin for Dermatomyositis. NEJM 330: 1392-1393 [Full Text]